Cargando…

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

BACKGROUND: Prostate cancer growth is primarily driven by testosterone and 5α-dihydrotestosterone. Abiraterone is an irreversible inhibitor of CYP17, and CYP17 inhibition is a required step in testosterone biosynthesis. Previous studies have shown that abiraterone trough levels are predictive of pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Myint, Zin W., Kolesar, Jill M., McCorkle, Joseph Robert, Wu, Jianrong, Ellis, Carleton S., Otto, Danielle E., Wang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578325/ https://www.ncbi.nlm.nih.gov/pubmed/36229939 http://dx.doi.org/10.12659/MSM.938091

Ejemplares similares

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Uchimoto, Taizo, et al.
Publicado: (2021)

Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis
por: Myint, Zin W., et al.
Publicado: (2020)

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
por: Lott, Felipe
Publicado: (2020)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials
por: Nakayama, Masahiko, et al.
Publicado: (2016)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
por: Schlack, Katrin, et al.
Publicado: (2016)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma
por: Yin, Ming, et al.
Publicado: (2007)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer
por: Sharma, Aditya Prakash
Publicado: (2017)

Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience
por: Purshouse, Karin, et al.
Publicado: (2019)

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
por: Tsaur, Igor, et al.
Publicado: (2021)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Case report: Incidental metastatic prostate cancer with undetectable PSA in pelvic lymphadenectomy
por: McLeay, Matthew T., et al.
Publicado: (2018)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
por: Mikah, Phillip, et al.
Publicado: (2016)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2023)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
por: Ueda, Takashi, et al.
Publicado: (2021)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA
por: Mašić, Silvija, et al.
Publicado: (2019)

Clinical Significance of Free-to-Total Prostate-Specific Antigen (PSA) Ratio in Advanced Prostate Cancer Patients with PSA Less than 0.1 ng/ml after Hormone Treatment
por: Kim, Dae Il, et al.
Publicado: (2012)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets
por: Patel, Amol, et al.
Publicado: (2020)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3vjuoea9vnuidu1m8u2o5hmqis